海思科：获得创新药HSK36357胶囊新适应症IND申请受理通知书

Core Viewpoint - Company Haisco (002653) has received a notice from the National Medical Products Administration regarding the acceptance of a clinical trial application for a new drug, HSK36357, which is developed for treating muscular dystrophy [1] Group 1: Drug Development - HSK36357 is a new small molecule drug with independent intellectual property rights developed by the company [1] - The drug has already been approved for clinical trials for the indication of "peripheral neuropathic pain" [1] - The current acceptance is specifically for clinical trials aimed at treating muscular dystrophy, including Becker muscular dystrophy and Duchenne muscular dystrophy [1]